Get Access to Encorafenib in India

Encorafenib is an oral medication approved by the FDA for the treatment of unresectable or metastatic melanoma. It is further specified for the use of patients with BRAF V600E or V500K mutation. Encorafenib is also indicated for the treatment of colorectal cancer in combination with cetuximab. In the case of colorectal cancer, the specific indication is for the metastatic CRC with BRAF V600E mutation. In melanoma treatment, it is used in combination of binimetinib. Braftovi is the trade name for this drug and is commercially available as 75mg capsules. Encorafenib in India is procured based on the expert advice through import channels.
Braftovi 75mg capsules are available in a bottle of 90 capsules. A commercial pack contains two such bottles. The dosage for melanoma is 450mg per day and CRC is 300mg per day. This can be altered based on the clinical experience and response to the medication by the treating physicians. This drug is indicated and approved only in adult patients and there is no credible evidence for paediatric cases. The duration of treatment is not clearly specified. It should be continued till disease progression or tolerability considerations are noted.
Encorafenib is an innovative drug developed by Novartis and further promoted by Array BioPharma. It was granted the approval by the US FDA in 2018. It is a kinase inhibitor that is known by its function of inhibiting BRAF gene. It has a unique mechanism of action that helps in slowing or stopping the growth of cancer cells.